Wockhardt share news and announcements
NSE: WOCKPHARMABSE: 532300Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,801.70down ₹53.80 (2.90%)BSE ₹1,801.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,855.50.
52-week range of traded prices to 23 Oct 2026
₹1,086.70Low, 23 Mar 2026₹2,422.30High, 1 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29,276 Cr311th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 71.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 5.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 8,79,19043.6% delivered
Wockhardt share news and announcements
1,008 announcements, routine notices left out, newest first. Page 13 of 21.
Sep 2015
28 Sep · News Verification
News about Wockhardt Limited.The media had reports that "Wockhardt's Waluj Plant Gets US FDA Approval".The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company.Wockhardt Limited has vide its letter inter-alia stated, "We have to inform you that the company has not received any such communication as mentioned in the said news item from US FDA. Please note that earlier on 27th May, 2015, the company has informed Exchanges about completion of inspection at our manufacturing unit at Waluz, Aurangabad by US FDA. As a standard protocol, the company keeps the Stock Exchanges informed about any price sensitive information under Clause 36 of the Listing Agreement or other relevant applicable laws."28 Sep · News Verification
Exchange has sought clarification from Wockhardt Limited, with respect to recent news item captioned "Wockhardt's Waluj Plant Gets US FDA Approval". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Aug 2015
10 Aug · Corporate action
Company has fixed Book Closure from September 5, 2015 to September 12, 2015 for the purpose of for Annual General Meeting and Preference Dividend
Jul 2015
Jun 2015
8 Jun · News Verification
News Verification : The media had reports that "Wockhardt's BP, antibiotic drugs recalled in the US.". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Wockhardt Limited has vide its letter inter-alia stated,"that the Company had already informed the exchange on 28th April, 2015 about recall of products. The recall stated in the said article forms part of the same. In present case, we do not have any important information/announcement to be shared."8 Jun · Legal
Exchange has sought clarification from Wockhardt Limited with respect to recent news item captioned "Wockhardt's BP, antibiotic drugs recalled in the US". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. Reply from the company is awaited.
May 2015
27 May · News Verification
News Verification : The media had reports that "US FDA has completed inspection of both Waluj, Chikalthana Facilities.". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Wockhardt Limited has vide its letter inter-alia stated, "that inspection of our manufacturing unit at H14/2 Waluj, Aurangabad, Maharashtra by US FDA has since been completed."27 May · Legal
Exchange has sought clarification from Wockhardt Limited with respect to recent news item captioned "US FDA has completed inspection of both Waluj, Chikalthana Facilities". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Apr 2015
Mar 2015
Feb 2015
27 Feb · Legal
Exchange has sought clarification from Wockhardt Limited with respect to recent news item captioned "FDA concern on Wockhardt plant . In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.4 Feb · Change in Company Secretary/Compliance Officer
Board noted the resignation of Mr. Nimesh S. Shah as Company Secretary and Compliance Officer of the Company with effect from close of working hours of February 9, 2015. Further, Ms. Amruta Avasare, Assistant Company Secretary will act as Compliance Officer of the Company till the appointment of new Company Secretary.
Jan 2015
23 Jan · Board meeting
Inter alia to consider and approve the unaudited financial results (consolidated and standalone) of the Company for the third quarter and nine months ended December 31, 2014.
Dec 2014
31 Dec · Legal
Exchange has sought clarification from Wockhardt Limited with respect to recent news item captioned "Wockhardt, Cadila & Hospira Voluntarily Recall Drugs in US". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Nov 2014
5 Nov · Legal
Exchange has sought clarification from Wockhardt Limited with respect to recent news item captioned "Wockhardt: US export ban may stay till 2015". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.4 Nov · Dividend
Interim Dividend will be paid to the shareholders of the Company on or before December 02, 2014.4 Nov · Corporate action
Company has fixed Record Date as November 15, 2014 for the purpose of Interim Dividend.3 Nov · Dividend
Board of Directors of the Company at their meeting held on November 3, 2014 have declared an Interim Dividend of Rs. 20/- per equity share of face value of Rs. 5/- each i.e @ 400 % for the financial year 2014-15 on 110,040,403 equity shares of the Company.